Q3 FY2026
Filed Nov 16, 2026Larimar completes nomlabofusp BLA submission; Q3 2026 net loss narrows to $31.1 million as R&D falls, cash runway runs into late Q2 2027
The net loss narrowed sharply year over year, mainly because R&D spending fell on lower third-party drug manufacturing activity, and the BLA submission is complete. Against that, G&A rose as commercial preparation accelerated, the company reports no revenue, cash, cash equivalents and marketable securities stood at $128.7 million, and the company projects runway only into late Q2 2027.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net loss, three months ended Sep 30, 2026GAAP | $31.1M | – | – |
| Net loss per common share (basic and diluted), three months ended Sep 30, 2026GAAP | $0.29 per common share | – | – |
| Research and development expenses, three months ended Sep 30, 2026GAAP | $25.9M | – | – |
| General and administrative expenses, three months ended Sep 30, 2026GAAP | $6.5M | – | – |
| Total operating expenses, three months ended Sep 30, 2026GAAP | $32.46M | – | – |
| Loss from operations, three months ended Sep 30, 2026GAAP | −$32.46M | – | – |
| Other income, net, three months ended Sep 30, 2026GAAP | $1.33M | – | – |
| Net loss, nine months ended Sep 30, 2026GAAP | $93.5M | – | – |
| Net loss per common share (basic and diluted), nine months ended Sep 30, 2026GAAP | $0.90 per common share | – | – |
| Research and development expenses, nine months ended Sep 30, 2026GAAP | $79M | – | – |
| General and administrative expenses, nine months ended Sep 30, 2026GAAP | $19M | – | – |
| Total operating expenses, nine months ended Sep 30, 2026GAAP | $97.93M | – | – |
| Loss from operations, nine months ended Sep 30, 2026GAAP | −$97.93M | – | – |
| Other income, net, nine months ended Sep 30, 2026GAAP | $4.40M | – | – |
| Net loss per preferred stock share (basic and diluted), three months ended Sep 30, 2026GAAP | $(2.85) | – | – |
| Net loss per preferred stock share (basic and diluted), nine months ended Sep 30, 2026GAAP | $(8.98) | – | – |
| Cash, cash equivalents and marketable securities, as of Sep 30, 2026other | $128.7M | – | – |
| Total assets, as of Sep 30, 2026GAAP | $140.5M | – | – |
| Total liabilities, as of Sep 30, 2026GAAP | $39.04M | – | – |
| Total stockholders' equity, as of Sep 30, 2026GAAP | $101.5M | – | – |
Capital returns
- No share repurchases or dividends are reported in the filing.
- Preferred stock: 500,000 shares issued and outstanding as of Sep 30, 2026, compared with 250,000 shares as of Dec 31, 2025. The filing does not describe the issuance or its terms.
- Common stock: 104,634,619 shares issued and outstanding as of Sep 30, 2026, compared with 83,090,392 as of Dec 31, 2025. Additional paid-in capital was $629,741 thousand as of Sep 30, 2026, compared with $512,779 thousand as of Dec 31, 2025.
What drove it
- Company explanation for lower R&D: the decrease of $44.9 million to $25.9 million in the quarter was primarily driven by a $19.3 million decrease in drug manufacturing activities at third-party manufacturers.
- Company explanation for nine-month R&D: the decrease from $94.9 million to $79.0 million was primarily driven by a $20.1 million decrease in drug manufacturing activities at third-party manufacturers, partially offset by an increase of $4.1 million in professional, software and consulting fees tied to ongoing and planned clinical trials, data analysis, FDA inspection readiness and BLA preparation costs.
- Company explanation for Q3 G&A: the increase from $4.6 million to $6.5 million primarily related to the acceleration of commercial activities ahead of the planned third quarter 2027 launch of nomlabofusp, if approved. The filing itemizes $0.6 million of professional fees for commercial consulting, $0.5 million of legal fees, $0.3 million of compensation costs for additional commercial and related headcount, and $0.3 million of stock compensation for 2026 grants.
- Company explanation for nine-month G&A: the increase from $13.6 million to $19.0 million primarily related to the same commercial preparation. The filing itemizes $2.2 million of professional fees for commercial consulting, $1.3 million of compensation costs, $1.0 million of legal fees and $0.5 million of stock compensation, associated with increased headcount period over period.
- Regulatory status per the filing: the rolling BLA for nomlabofusp seeking accelerated approval using FXN as a novel surrogate endpoint has been completed. The filing states that FDA reviewed open label study data in a briefing package and confirmed in minutes of a Type B pre-BLA meeting that the existing data package appears capable of supporting submission and review.
- Other income, net decreased to $1,329 thousand in the quarter from $1,787 thousand a year earlier, and to $4,402 thousand for nine months from $5,304 thousand. The filing does not explain the change.
Concerns
- The company reports no revenue in the filing and remains in a net loss position, with net loss of $31.1 million in the quarter and $93.5 million for nine months.
- Cash, cash equivalents and marketable securities were $128.7 million as of Sep 30, 2026, and the projected cash runway extends only into late Q2 2027.
- Total liabilities fell to $39,038 thousand from $67,757 thousand at Dec 31, 2025, while total stockholders' equity rose to $101,466 thousand from $78,085 thousand, and the filing shows more preferred stock and common shares outstanding. The filing does not describe the financing that accompanied these changes.
- The filing states that completing the BLA submission does not assure acceptance for filing or accelerated approval, that FDA may require additional information or studies, and that FDA may not agree that skin FXN is an acceptable surrogate endpoint.
- G&A is rising as commercial preparation accelerates, and the filing describes further commercial preparation ahead of a planned launch that is contingent on approval.
What to watch
- BLA submission acceptance: early 2027, per the company's milestone list.
- Open label study safety update: Q1 2027.
- U.S. approval: mid-2027, a matter of FDA review.
- Obtaining and monetizing the Rare Pediatric Disease Priority Review Voucher: mid-2027, if approved.
- U.S. launch: targeted for Q3 2027, if approved.
- Cash runway: the company projects it extends into late Q2 2027. The filing does not describe any financing plans in detail beyond evaluating options to support global commercialization.
- FORWARD-FA, the global confirmatory Phase 3 study, is enrolling patients, and its progress is one of the next 12 months' registrational catalysts per the CEO.
Balance sheet and cash flow
- Cash and cash equivalents were $76,986 thousand as of Sep 30, 2026, compared with $85,412 thousand as of Dec 31, 2025.
- Marketable securities were $51,672 thousand as of Sep 30, 2026, compared with $51,440 thousand as of Dec 31, 2025.
- Total current liabilities were $35,645 thousand as of Sep 30, 2026, compared with $64,795 thousand as of Dec 31, 2025. Accrued expenses were $29,155 thousand, compared with $58,474 thousand at Dec 31, 2025.
- Accumulated deficit was $(528,361) thousand as of Sep 30, 2026, compared with $(434,831) thousand as of Dec 31, 2025.
- Total stockholders' equity was $101,466 thousand as of Sep 30, 2026, compared with $78,085 thousand as of Dec 31, 2025.
- The company projects its cash runway into late Q2 2027.
- No cash flow statement is included in the filing, so operating cash flow, investing cash flow, financing cash flow and free cash flow are not reported.
Analysis
Larimar reports a third quarter of 2026 with a net loss of $31.1 million, or $0.29 per common share, compared with $47.7 million, or $0.61 per common share, in the third quarter of 2025. The improvement is driven by research and development expense, which fell to $25.9 million from $44.9 million. The company explains the decline primarily by a $19.3 million decrease in drug manufacturing activities at third-party manufacturers. Total operating expenses were $32,464 thousand against $49,499 thousand. General and administrative expense moved the other way, rising to $6.5 million from $4.6 million, which the company attributes to accelerating commercial preparation for a planned third quarter 2027 launch, if nomlabofusp is approved. No revenue line appears in the filing, so the company remains a pre-revenue clinical-stage business.
Nine-month figures follow the same pattern. The net loss was $93.5 million, or $0.90 per common share, against $103.2 million, or $1.50 per common share, a year earlier. Nine-month R&D was $79.0 million against $94.9 million, with the company citing a $20.1 million decrease in third-party manufacturing activity partly offset by $4.1 million of higher professional, software and consulting fees. Nine-month G&A was $19.0 million against $13.6 million. The per-share figures reflect a larger share count. Weighted-average common shares were 104,211,155 in the quarter against 78,324,767 a year earlier, and the filing also reports preferred stock per-share losses of $(2.85) for the quarter and $(8.98) for nine months.
On the balance sheet, cash, cash equivalents and marketable securities totaled $128.7 million as of September 30, 2026. Total assets were $140,504 thousand, total liabilities were $39,038 thousand and stockholders' equity was $101,466 thousand. Against December 31, 2025, accrued expenses fell from $58,474 thousand to $29,155 thousand, and stockholders' equity rose from $78,085 thousand. Preferred shares outstanding increased from 250,000 to 500,000 and common shares outstanding rose from 83,090,392 to 104,634,619. The filing does not describe the transactions behind these share changes, so the reader should check the 10-Q for the financing terms. The company projects cash runway into late Q2 2027, which sits close to the planned mid-2027 approval timeline and places any financing need ahead of the launch.
The operational update centers on the BLA. The company says it completed a rolling submission seeking accelerated approval using FXN as a novel surrogate endpoint, and that FDA confirmed in minutes of a Type B pre-BLA meeting that the existing data package appears capable of supporting submission and review. The filing also states that acceptance for filing and accelerated approval are not assured. The company has no guidance figures in the filing, so no financial outlook can be compared with actuals. The forward milestones are BLA acceptance in early 2027, a safety update in Q1 2027, U.S. approval in mid-2027 and a targeted Q3 2027 launch.
Management, verbatim
Completing the BLA submission for nomlabofusp marks a major milestone for Larimar and the Friedreich's ataxia (FA) community.
Carole Ben-Maimon, M.D., Chief Executive Officer
Not in the filing
stated, not guessed- Revenue and any revenue line: the filing reports no revenue figure for any period.
- Percentage changes for net loss, R&D, G&A, operating expenses, other income and per-share figures: the filing does not print them.
- Prior-quarter (Q2 2026) figures: the filing does not present a sequential comparison.
- Cash flow statement: operating, investing and financing cash flows and free cash flow are not included.
- Cash and cash equivalents and marketable securities as of Sep 30, 2025: not printed.
- Financial guidance or outlook figures: none are provided. Only regulatory and timing milestones appear.
- Prior-period outlook: not provided, so no comparison against guidance is possible.
- Terms and proceeds of the preferred stock and common share issuance behind the balance sheet changes: not described.
- Share price reaction and analyst consensus estimates: not provided in the documents.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.